Form 4: Bicara CFO Sells Shares Under Pre-Planned 10b5-1 Plan

Bicara Therapeutics' Chief Financial Officer, Ivan Hyep, executed a pre-planned sale of 1,882 common shares after exercising stock options.

Summary

• Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc. (BCAX), engaged in a transaction on January 22, 2026.
• The transaction involved the exercise of stock options to acquire 1,882 shares of common stock at an exercise price of $3.7898 per share.
• Immediately following the option exercise, 1,882 shares of common stock were sold at a weighted average price of $18.1522 per share.
• The shares were sold in multiple transactions at prices ranging from $18.15 to $18.18, inclusive.
• Both the option exercise and the subsequent sale were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
• Following these transactions, Ivan Hyep beneficially owns 145,355 shares of common stock directly.
• Additionally, 65,462 derivative securities (stock options) remain beneficially owned directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine, pre-planned insider transaction (option exercise and sale) by a CFO, which is a common occurrence and does not inherently indicate strong positive or negative sentiment about the company's prospects. The use of a 10b5-1 plan mitigates any potential negative perception of insider selling.

Positives

• The Chief Financial Officer realized a profit from the exercise of stock options and subsequent sale of shares, indicating personal financial gain.
• The transactions were conducted under a Rule 10b5-1 trading plan, which demonstrates pre-planning and adherence to insider trading regulations, potentially reducing concerns about opportunistic selling.

Negatives

• The sale of shares by a key executive, even if pre-planned, can sometimes be perceived negatively by the market, although the number of shares sold is relatively small compared to total holdings.

Future Outlook

This filing is a transactional report and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis for Bicara Therapeutics Inc.

Stakeholder Impact

• Shareholders: May observe a minor reduction in direct insider holdings, but the pre-planned nature of the transaction under a 10b5-1 plan typically lessens concerns about management's confidence in the company's future.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Form 4, insider trading, stock option exercise, share sale, CFO transaction, 10b5-1 plan